Like Jak1/2 and B2m, Ankrd52 sgRNAs exhibited time-dependent enrichment in tumor cells in the presence of T cells (Fig. 3c–e; Supplementary Fig. 6c–g; Supplementary Data 2), providing direct evidence that loss of ANKRD52 conferred resistance to T cell killing. Here, ANKRD52 is linked to neoplasm.